Investing in Transformative Oncology Therapies with Maina Bhaman Sofinnova Partners

Published: Feb. 2, 2021, 5:38 p.m.

Maina Bhaman, Partner, Capital Funds, Sofinnova Partners has a long record as a successful healthcare investor in oncology, hearing, cardiovascular and cell and gene therapy. She talks about their recent investments in Myricx Pharma, a startup from Imperial College and the Francis Crick Institute in London focused on inhibiting the NMT enzyme to kill MYC-driven cancer cells and Catamaran Bio focusing on CAR-NK cells to kill solid tumors by addressing the tumor microenvironment.

#SofinnovaPartners #Biotech #Funding #CARNK #Cancer

SofinnovaPartners.com

Download the transcript here